Organicell Regenerative Medicine, Inc.
OCEL
Other OTC2.74
USD
-0.01
- -
Organicell Regenerative Medicine, Inc.
OCEL
(Other OTC)
Recent
price
2.74
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Organicell Regenerative Medicine, Inc. (OCEL) develops and commercializes biologics and regenerative therapies derived from perinatal sources for treating inflammatory, autoimmune, and degenerative diseases. The company offers proprietary products including Organicell Flow, a mesenchymal cellular therapy for conditions such as osteoarthritis and multiple sclerosis; Discogell, an injectable treatment for degenerative disc disease; and BioPhase solutions for advanced cellular processing and delivery. Its pipeline encompasses investigational therapies targeting pulmonary disorders, cardiovascular conditions, and orthopedic injuries, with services extending to custom biologics manufacturing and clinical trial support for research institutions and healthcare providers [ from prior]. Founded in 2014 and headquartered in Miami, Florida, Organicell operates primarily in the United States with research and distribution networks extending to select international markets in Europe and Latin America. The company serves medical professionals, clinics, hospitals, and biotech partners in the regenerative medicine sector, focusing on perinatal-derived mesenchymal stem cells and exosomes as key modalities. Subsidiaries include Organicell Bio Corp. for production scaling, with no current parent company affiliation. In the last two years, Organicell completed a significant private placement funding round in 2024 raising over $5 million to advance clinical trials and manufacturing expansion. The company launched Discogell in early 2025 following FDA clearance for investigational use and formed a strategic alliance with a leading orthopedic network for Phase II trials in spine regeneration. Additionally, Organicell reorganized its leadership in mid-2025, appointing a new Chief Scientific Officer to oversee pipeline acceleration amid growing demand for exosome-based therapies.
RETRANSMISSION: Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Regenerative Medicine Rebranding to ZEO ScientifiX
Organicell Announces 1-for-200 Reverse Stock Split
Organicell Reports Interim Results of Phase 1/2A Research Program